Credit: Shutterstock photoTVAX Biomedical, a biotech company focused on cancer cell vacination and T cell cancer treatment, withdrew its plans for an initial public offering on Thursday, citing poor market conditions. The Lenexa, KS-based company was founded in 2004 and was looking to raise $20 million to fund clinical trials for its product candidate, TVI-Brain-1. Roth Capital was set to be the sole bookrunner on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
